Champions Oncology Files Definitive Proxy Statement

TL;DR

CHMP proxy statement filed. Standard shareholder meeting stuff.

AI Summary

Champions Oncology, Inc. filed a Definitive Proxy Statement (DEF 14A) on August 27, 2024. The filing pertains to the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. The company's fiscal year ends on April 30th, and its principal executive offices are located in Baltimore, MD.

Why It Matters

This filing is a standard regulatory requirement for public companies, providing shareholders with information necessary to vote on company matters at upcoming meetings.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing, which is a standard disclosure document for public companies and does not inherently indicate new risks.

Key Players & Entities

• CHAMPIONS ONCOLOGY, INC. (company) — Registrant
• 0001628280-24-038540 (filing_id) — Accession Number
• 20240827 (date) — Filing Date
• BALTIMORE, MD (location) — Business Address
• 0430 (date) — Fiscal Year End

FAQ

Key Financial Figures

• $0.001 — of the Company's common stock par value $0.001 per share (the "Shares"). The Board of

Filing Documents

• scheduledef14a_2024.htm (DEF 14A) — 455KB
• chart-230501d8abea4fe0861.jpg (GRAPHIC) — 88KB
• chart-349c77a5b90b482faa8.jpg (GRAPHIC) — 90KB
• proxycardinfoa04.jpg (GRAPHIC) — 5KB
• 0001628280-24-038540.txt ( ) — 709KB

From the Filing

DEF 14A 1 scheduledef14a_2024.htm DEF 14A Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12 Champions Oncology, Inc. (Name of Registrant as Specified in Its Charter) NA (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box) No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. 2 (1) Title of each class of securities to which transaction applies (2) Aggregate number of securities to which transaction applies (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined) (4) Proposed maximum aggregate value of transaction (5) Total fee paid o Fee paid previously with preliminary materials. o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid (2) Form, Schedule or Registration Statement No. (3) Filing Party (4) Date Filed Champions Oncology, Inc. One University Plaza, Suite 307 Hackensack, New Jersey 07601 Notice of Annual Meeting of Stockholders to be held on October 14, 2024 To the Stockholders of Champions Oncology, Inc. The Annual Meeting of Stockholders of Champions Oncology, Inc., a Delaware corporation (the "Company"), will be held at the Company's headquarters, located at One University Plaza, Suite 307, Hackensack, New Jersey 07601, on Monday, October 14, 2024 at 900 a.m., Eastern time, for the following purposes 1. Elect the seven Board of Director nominees named in the accompanying Proxy Statement to the Board of Directors for the ensuing year and until his successor has been elected and qualified, or until his earlier death, resignation or removal 2. Ratify the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending April 30, 2025 3. Approve a non-binding advisory resolution relating to the compensation of our named executive officers and 4. Transact such other business as may properly come before the meeting or any adjournments or postponements thereof. The Board of Directors has fixed August 26, 2024 as the Record Date for the determination of stockholders entitled to notice of, and to vote at, the meeting. 3 UNLESS YOU PROVIDE SPECIFIC INSTRUCTIONS AS TO HOW TO VOTE, BROKERS MAY NOT VOTE YOUR SHARES OF COMMON STOCK ON THE ELECTION OF DIRECTORS OR THE NON-BINDING ADVISORY RESOLUTION RELATING TO THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on October 14, 2024 Pursuant to rules and regulations adopted by the Securities and Exchange Commission (the SEC), we have elected to provide access to our proxy materials over the Internet, allowing us to provide the information stockholders need, while lowering delivery and printing expenses. On or about September 3, 2024, we will mail to our stockholders a notice containing instructions on how our stockholders may access online our 2024 Proxy Statement and 2024 Annual Report on Form 10-K. Our Form 10-K does not constitute a part of the proxy solicitation material, but provides you with additional information about the Company. These materials are available on the following website httpswww.iproxydirect.comCSBR . We invite your attention to each of these documents, and we invite you to attend the Annual Meeting of Stockholders, in person. By Order of the Board of Directors s Ronnie Morris Ronnie Morris Chief Executive Officer Hackensack, New Jersey August 27, 2024 EVEN IF YOU PLAN TO ATTEND THE MEETING IN PERSON, PLEASE VOTE YOUR SHARES ONLINE, OR UPON REQUEST, OBTAIN A PROXY CARD AND RETURN IT PROMPTLY TO OUR TABULATOR. IF YOU ATTEND THE MEETING IN PERSON, YOU MAY REVOKE YOUR PROXY AND VOTE IN PERSON AT THE MEETING. 4 Champions Oncology, Inc. One University Plaza, Suite 307 Hackensack, New Jersey 07601 (551) 206-8104 Proxy Statement For Annual Meeting of Stockholders Approximate Date of Mailing September 3, 2024 The accompanying proxy is solicited by the board of directors (the Board of Directors or the Board) of Champions Oncology, Inc., a Delaware corporation,

View Full Filing

View this DEF 14A filing on SEC EDGAR